Telomir Pharmaceuticals, Inc. (TELO) Stock Price & Analysis
Telomir Pharmaceuticals, Inc. (TELO) fell 0.85% to USD 1.16 as of September 8, 2026 at 12:19 UTC, according to Nexqual real-time market data.
TELO last closed at USD 1.17; the session ranged USD 1.16–1.18 on volume of 33,919 shares. Market capitalization is $79.78M, with a 52-week range of USD 0.89–2.09 (NCM). Source: Nexqual, September 8, 2026 at 12:19 UTC.
Key Statistics (as of September 8, 2026 at 12:19 UTC)
| Price | USD 1.16 |
|---|---|
| Change | ▼ 0.85% (down) |
| Previous Close | USD 1.17 |
| Open | USD 1.17 |
| Day Range | USD 1.16 – 1.18 |
| 52-Week Range | USD 0.89 – 2.09 |
| Volume | 33,919 shares |
| Market Cap | $79.78M |
| Exchange | NCM |
Technical Analysis (TELO)
Nexqual's technical model rates TELO "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 12:19 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.62 (neutral) |
| vs SMA50 | Below (USD 1.17) |
| MACD | -0.01 (negative) |
Analyst Ratings (TELO)
Wall Street analysts rate TELO "None", per Nexqual as of September 8, 2026 at 12:19 UTC.
| Consensus Rating | None |
|---|
Earnings (TELO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.03 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.17 vs est -0.08 ▼ miss |
| 2025-03-31 | USD -0.07 vs est -0.1 ▲ beat |
| 2024-12-31 | USD -0.1 vs est -0.05 ▼ miss |
Source: Nexqual, September 8, 2026 at 12:19 UTC.
Financials & Fundamentals (TELO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -213.10% |
| Debt / Equity | 2.72 |
| Current Ratio | 16.14 |
| Total Cash | $5.17M |
| Total Debt | $136,898 |
| Free Cash Flow | $-3.07M |
Source: Nexqual, September 8, 2026 at 12:19 UTC.
Financial Health Score (TELO)
Nexqual rates Telomir Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 12:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $5M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -213%, ROA -122.8% |
Ownership (TELO)
| Insider Ownership | +46.00% |
|---|---|
| Institutional Ownership | +4.31% |
| Shares Outstanding | 68.77M |
| Float | 45.73M |
| Short % of Float | +1.47% |
Source: Nexqual, September 8, 2026 at 12:19 UTC.
Leadership (TELO)
Telomir Pharmaceuticals, Inc. is led by Erez Aminov (age 47), Chairman of the Board & CEO, per Nexqual as of September 8, 2026 at 12:19 UTC.
| Chairman of the Board & CEO | Erez Aminov (age 47) |
|---|---|
| Chief Financial Officer | Andriy Mushak (age 42) |
| Chief Scientific Advisor | Itzchak Angel |
Major Backers & Investors (TELO)
Notable institutional backers of Telomir Pharmaceuticals, Inc. include Fidelity, according to Nexqual as of September 8, 2026 at 12:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.42% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.03% |
| Geode Capital | 0.49% |
| BlackRock | 0.46% |
Source: Nexqual, September 8, 2026 at 12:19 UTC.
From Telomir Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
- It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MIRA | MIRA Pharmaceuticals, Inc. | USD 0.76 | ▼ 10.12% |
| KAPA | Kairos Pharma, Ltd. | USD 1.84 | ▲ 16.46% |
| SUGP | SU Group Holdings Limited | USD 0.64 | ▲ 1.91% |
| PLRZ | Polyrizon Ltd. | USD 11.24 | ▼ 10.15% |
| PMN | ProMIS Neurosciences Inc. | USD 12.6 | ▼ 9.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:19 UTC. This page is informational and not investment advice.